BusinessAbeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten DiseaseBy Nasdaq OMXApr 20, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive OfficerBy Nasdaq OMXApr 2, 2018, 12:15 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten DiseaseBy Nasdaq OMXFeb 12, 2018, 1:45 PM UTC
BusinessAbeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene TherapiesBy Nasdaq OMXOct 16, 2017, 12:26 PM UTC
BusinessAbeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIABy Nasdaq OMXOct 11, 2017, 12:19 PM UTC
BusinessAbeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the MesaBy Nasdaq OMXOct 6, 2017, 12:25 PM UTC
BusinessAbeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102By Nasdaq OMXSep 28, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Announces Upcoming Conference ParticipationBy Nasdaq OMXSep 22, 2017, 12:45 PM UTC
